레지오넬라균 검사 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of Legionella testing Market

The global Legionella testing market was valued at USD 379.3 million in 2025 and is projected to grow from USD 415.1 million in 2026 to USD 883.8 million by 2034, exhibiting a CAGR of 9.90% during the forecast period (2026-2034). The market is witnessing steady expansion due to the rising prevalence of Legionnaires' disease, increasing awareness regarding waterborne infections, and the growing adoption of rapid diagnostic technologies. In 2025, North America dominated the market with a 39.50% share, supported by strong regulatory frameworks and advanced healthcare infrastructure.

Market Overview

Legionella is a bacterial species commonly found in freshwater environments such as ponds, lakes, showers, hot tubs, cooling towers, and water storage systems. Under favorable conditions, particularly temperatures between 20°C and 40°C, the bacteria multiply and can cause respiratory illnesses such as Legionnaires' disease and Pontiac fever.

Growing public health concerns, especially in developed countries, have led to stringent regulations for regular water testing. Following the increased prevalence of Legionella infections in the U.S. since 1997, authorities implemented mandatory testing of water systems. According to WHO data (2022), approximately 10-15 cases per million population are detected annually across the U.S., Europe, and Australia.

Impact of COVID-19 on the Market

During the COVID-19 pandemic, the market experienced temporary slow growth due to manufacturing disruptions, supply chain challenges, and healthcare systems prioritizing coronavirus testing. Additionally, similarities in clinical symptoms between COVID-19 and Legionnaires' disease resulted in reduced Legionella testing rates.

However, the post-pandemic period has created renewed growth opportunities. Prolonged building closures led to stagnant water systems, increasing the risk of Legionella proliferation. In 2021, the CDC recommended testing water systems such as hot tubs and storage tanks before reopening facilities. This has significantly boosted demand for Legionella testing solutions in 2025 and beyond.

Market Trends

Growing Adoption of Rapid Testing Methods

The market is witnessing a shift from traditional culture methods to advanced diagnostic technologies such as Urine Antigen Testing (UAT) and Polymerase Chain Reaction (PCR).

• PCR testing offers high sensitivity (95-99%) and detects multiple Legionella serotypes with faster turnaround times.
• Real-time PCR kits are increasingly adopted for hospital-based and onsite testing.
• Rapid molecular diagnostics are improving accuracy and enabling early disease detection.

These technological advancements are key contributors to the projected growth from USD 415.1 million in 2026 to USD 883.8 million by 2034.

Market Growth Drivers

1. Rising Prevalence of Legionnaires' Disease

Increasing global cases are driving demand for testing kits. The U.S. Department of Labor reports approximately 6,000 Legionella cases annually in the U.S. Hospital-acquired infections are also a concern. A study in Taiwan revealed that 63% of surveyed hospitals tested positive for Legionella pneumophila in their water systems.

2. Stringent Regulatory Policies

Governments worldwide are enforcing water management guidelines. The WHO provides seven principal guidance documents for risk management. In Europe, the European Working Group for Legionella Infections (EWGLI) supports surveillance programs. Such regulatory emphasis is strengthening market growth.

Market Restraints

Despite strong growth prospects, limited awareness in underdeveloped countries restrains market expansion. In countries like India, Legionella infections are often underdiagnosed due to overlapping symptoms with pneumonia and tuberculosis. High costs of advanced diagnostics such as real-time PCR and lack of infrastructure also hinder adoption in emerging markets.

Segmentation Analysis

By Type

The market is segmented into culture media, urine antigen testing, PCR, serology tests, and direct fluorescent antibody methods.

• Urine Antigen Testing (UAT) held the largest market share of 42.12% in 2026, due to affordability and same-day results. However, it primarily detects LP1 species.
• PCR testing is projected to witness the fastest growth due to superior sensitivity and accuracy.

By End-User

Segments include hospitals & clinics, clinical laboratories, and environmental testing sites.

• Clinical laboratories dominated the market and are expected to maintain leadership due to rising disease prevalence and advanced diagnostic penetration.
• Environmental testing is expanding rapidly due to onsite testing solutions and regulatory mandates.

Regional Insights

North America

The market size in North America reached USD 149.65 million in 2025. Strong regulatory enforcement, high awareness, and a large geriatric population drive demand.

Europe

Europe holds the second-largest share due to increasing outbreaks and adoption of PCR testing.

Asia Pacific

Asia Pacific is projected to grow at the highest CAGR through 2034, supported by improving healthcare infrastructure and rising awareness.

Competitive Landscape

The market is consolidated, with key players including Abbott, Thermo Fisher Scientific, Bio-Rad Laboratories, Merck KGaA, IDEXX Corporation, BD, bioMerieux, and Eurofins Scientific. Companies are focusing on mergers, acquisitions, and product launches to expand their portfolios.

Conclusion

The global Legionella testing market is set for strong growth, rising from USD 379.3 million in 2025 to USD 883.8 million by 2034, driven by increasing disease prevalence, stringent water safety regulations, and rapid adoption of advanced diagnostic technologies such as PCR and UAT. While limited awareness in emerging economies poses challenges, expanding regulatory frameworks and technological innovations are expected to sustain long-term market expansion. As governments and healthcare institutions prioritize water safety and infection prevention, Legionella testing will remain a critical component of global public health strategies.

Segmentation

By Type

• Culture Media
• Urine Antigen Testing (UAT)
• Polymerase Chain Reaction (PCR)
• Serology
• Direct Fluorescent Antibody (DFA) Test

By End-User

• Hospitals & Clinics
• Clinical Laboratories
• Others

By Geography

• North America (By Type, End-User, and Country)
  • U.S.
  • Canada
• Europe (By Type, End-User, and Country/Sub region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific (By Type, End-User, and Country/Sub region)
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Taiwan
  • Indonesia
  • Rest of Asia Pacific
• Latin America (By Type, End-User, and Country/Sub region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, End-User, and Country/Sub region)
  • South Africa
  • GCC
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Legionella Infection, By Key Countries
• 4.2. Key Industry Developments - Merges, Acquisitions and Partnerships
• 4.3. Technological Advancements in Legionella Testing Kits
• 4.4. Regulatory Scenario, By Key Countries
• 4.5. Impact of COVID-19 on the Market

5. Global Legionella Testing Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Culture Media
  • 5.1.2. Urine Antigen Testing (UAT)
  • 5.1.3. Polymerase Chain Reaction (PCR)
  • 5.1.4. Serology
  • 5.1.5. Direct Fluorescent Antibody Test (DFA)
• 5.2. Market Analysis, Insights and Forecast - By End User
  • 5.2.1. Hospitals & Clinics
  • 5.2.2. Clinical Laboratories
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Legionella Testing Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Culture Media
  • 6.1.2. Urine Antigen Testing (UAT)
  • 6.1.3. Polymerase Chain Reaction (PCR)
  • 6.1.4. Serology
  • 6.1.5. Direct Fluorescent Antibody Test (DFA)
• 6.2. Market Analysis, Insights and Forecast - By End User
  • 6.2.1. Hospitals & Clinics
  • 6.2.2. Clinical Laboratories
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Legionella Testing Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Culture Media
  • 7.1.2. Urine Antigen Testing (UAT)
  • 7.1.3. Polymerase Chain Reaction (PCR)
  • 7.1.4. Serology
  • 7.1.5. Direct Fluorescent Antibody Test (DFA)
• 7.2. Market Analysis, Insights and Forecast - By End User
  • 7.2.1. Hospitals & Clinics
  • 7.2.2. Clinical Laboratories
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.3.1. U.K
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Rest of Europe

8. Asia Pacific Legionella Testing Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Culture Media
  • 8.1.2. Urine Antigen Testing (UAT)
  • 8.1.3. Polymerase Chain Reaction (PCR)
  • 8.1.4. Serology
  • 8.1.5. Direct Fluorescent Antibody Test (DFA)
• 8.2. Market Analysis, Insights and Forecast - By End User
  • 8.2.1. Hospitals & Clinics
  • 8.2.2. Clinical Laboratories
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
  • 8.3.4. India
  • 8.3.5. Australia
  • 8.3.6. Taiwan
  • 8.3.7. Indonesia
  • 8.3.8. Rest of Asia Pacific

9. Latin America Legionella Testing Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Culture Media
  • 9.1.2. Urine Antigen Testing (UAT)
  • 9.1.3. Polymerase Chain Reaction (PCR)
  • 9.1.4. Serology
  • 9.1.5. Direct Fluorescent Antibody Test (DFA)
• 9.2. Market Analysis, Insights and Forecast - By End User
  • 9.2.1. Hospitals & Clinics
  • 9.2.2. Clinical Laboratories
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Rest of Latin America

10. Middle East & Africa Legionella Testing Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Culture Media
  • 10.1.2. Urine Antigen Testing (UAT)
  • 10.1.3. Polymerase Chain Reaction (PCR)
  • 10.1.4. Serology
  • 10.1.5. Direct Fluorescent Antibody Test (DFA)
• 10.2. Market Analysis, Insights and Forecast - By End User
  • 10.2.1. Hospitals & Clinics
  • 10.2.2. Clinical Laboratories
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.3.1. GCC
  • 10.3.2. South Africa
  • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Quidel Corporation
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. Abbott
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Merck KGaA
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. Bio-Rad Laboratories, Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Thermo Fisher Scientific Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. BD
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. bioMerieux
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. IDEXX Corporation
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. financials (Based on Availability)
  • 11.2.9. Eurofins Scientific
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. financials (Based on Availability)